Unhealthy gut microbiomes in mice remodelled into more healthy ones
Scientists have shown that there are molecules to remodel the gut microbiome and turn an unhealthful gut into a more healthful one for the first time.
List view / Grid view
Scientists have shown that there are molecules to remodel the gut microbiome and turn an unhealthful gut into a more healthful one for the first time.
The structure of a key receptor involved in tumour metastasis has been imaged in a study, providing opportunities to develop cancer treatments.
Libraries of more than 9,000 macrocyclic molecules below 1 KDa have been generated, small enough to cross cell membranes and reach targets.
A new platform has enabled an unprecedented level of control over individual molecules and particles on a chip for high-throughput analysis.
A new experiment has not only slowed the progression of the prion disease, scrapie, it also extended the lives of prion-infected mice
Molecular Devices, LLC, today announced the launch of the next generation of its FLIPR® Penta High-Throughput Cellular Screening System.
Researchers have discovered a new combination therapy to treat drug-resistant acute lymphoblastic leukaemia, tested in pre-clinical trials.
Researchers have developed a chip which facilitates and accelerates active substance production, characterisation and biological effectiveness.
Treatments for chronic inflammatory diseases are one step closer as a new study discovers a way to stop inflammation in its tracks.
Current technologies that measure molecular interactions for drug discovery slow down and complicate screening. Dianthus is the answer to the demands for fast, non-stop, highly sensitive hit identification, hit validation and lead optimisation.
Cell line development is a major step for examining the efficiency of drug discovery, toxicity and in vitro testing. It reduces time, effort and cost, which minimises the chance of research drugs failing at the clinical trial stage. This stage involves the production of recombinant proteins such as monoclonal antibodies,…
Small molecule drug discovery has long been the domain of pharmaceutical companies, and that’s not likely to change anytime soon. But there’s a cadre of universities and nonprofit research institutes that have embraced drug development at its earliest stages, in some cases identifying and optimising compounds that target possible disease-driving…
An online compound library consisting of the structure of over a billion molecules could be the future of drug discovery...
A natural antibiotic was found to be made from an enzyme, through it triggering chemical reactions that help the production of the bacterial toxin...
A mouse study has revealed that triple-negative breast cancer could be tackled by using recombinant Tinagl1 in therapy targeting signalling pathways...